A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer
OBJECTIVES: I. Determine the clinical effectiveness (i.e., objective tumor response, time to
treatment failure, and survival) of perillyl alcohol in patients with previously treated
metastatic breast cancer. II. Define the acute and chronic toxic effects of perillyl alcohol
in this patient population.
OUTLINE: Patients are given oral perillyl alcohol 4 times per day. Dose escalation of
perillyl alcohol may occur in individual patients if no unacceptable toxicity is observed.
Treatment is continued as long as the patient benefits from treatment, does not show
progressive disease, and does not experience irreversible or life threatening toxicity.
Patients are evaluated for response monthly while receiving treatment on this study.
Patients are followed at 2-4 weeks after the last treatment.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued over 2 years.
Primary Purpose: Treatment
Howard H. Bailey, MD
University of Wisconsin, Madison
United States: Federal Government
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|